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Abstract 24 
The influenza pandemic that emerged in 2009 provided an unprecedented 25 
opportunity to study adaptation of a virus recently acquired from an animal source 26 
during human transmission. In the UK, the novel virus spread in three temporally 27 
distinct waves between 2009 and 2011. Phylogenetic analysis of complete viral 28 
genomes showed that mutations accumulated over time. Second and third wave 29 
viruses replicated more rapidly in human airway epithelial (HAE) cells than first wave 30 
virus. In infected mice, weight loss varied between viral isolates from the same wave 31 
but showed no distinct pattern with wave, and did not correlate with viral load in the 32 
mouse lungs or severity of disease in the human donor. However, second and third 33 
wave viruses induced less interferon-α in the infected mouse lungs.  NS1 protein, an 34 
interferon antagonist, had accumulated several mutations in second and third wave 35 
viruses. Recombinant viruses with third wave NS gene induced less interferon in 36 
human cells but this alone was did not account for increased virus fitness in HAE 37 
cells. Mutations in HA and NA genes in third wave viruses caused increased binding 38 
to α-2,6 sialic acid, and enhanced infectivity in human mucus. A recombinant virus 39 
with these two segments replicated more efficiently in HAE cells. A mutation in PA 40 
(N321K) enhanced polymerase activity of third wave viruses and also provided a 41 
replicative advantage in HAE cells. Therefore, multiple mutations allowed 42 
incremental changes in viral fitness which together may have contributed to the 43 
apparent increase in severity of A(H1N1)pdm09 influenza during successive waves. 44 
  45 
Importance 46 
Although most people infected with the 2009 pandemic influenza virus had mild or 47 
unapparent symptoms, some suffered severe and devastating disease. The reasons 48 
for this variability were unknown but the numbers of severe cases increased during 49 
successive waves of human infection in the UK. To determine the causes of this 50 
variation, we studied genetic changes in virus isolates from individual hospitalized 51 
patients. There were no consistent differences between these viruses and those 52 
circulating in the community, but we found multiple evolutionary changes that in 53 
combination over time increased the virus’s ability to infect human cells. These 54 
adaptations may explain the remarkable ability of A(H1N1)pdm09 virus to continue to 55 
circulate despite widespread immunity, and the apparent increase in severity of 56 
influenza over successive waves of infection.  57 
Introduction 58 
In 2009 a novel H1N1 influenza virus (A(H1N1)pdm09) crossed the species barrier 59 
from swine into humans causing the first influenza pandemic of the 21st century. The 60 
swine-origin virus displayed a complex genotype including antigen gene segments 61 
derived from swine-adapted influenza viruses that had previously circulated on 62 
different continents, and an internal gene cassette known as the triple reassortant 63 
genotype (TRIG) first described in pigs in the late 1990s (1–3).  The TRIG cassette 64 
contained two polymerase components, PB2 and PA, from an avian virus and the 65 
other, PB1, from a human-adapted virus.  The NP, HA and NS gene segments of the 66 
pandemic H1N1 2009 virus were acquired from the classical swine virus lineage that 67 
has circulated in pigs since 1918 and had been maintained in North American swine 68 
viruses (4, 5). Classical swine influenza viruses shared an origin with the human 69 
H1N1 seasonal influenza viruses but the two had since undergone species-specific 70 
mutations in their respective hosts. The genetic distance between the HA genes was 71 
sufficient to cause a pandemic, despite the circulation of seasonal H1 viruses in 72 
humans from 1977 until 2009.  The A(H1N1)pdm09 NP gene had adaptations 73 
associated with evasion of MxA from swine or humans (6). Finally, RNA segment 8 74 
encoding NS1 and NEP proteins had accumulated many mutations that 75 
differentiated it from the NS segment of human-adapted influenza viruses. Notably 76 
the swine virus NS1 protein had become truncated through a termination codon at 77 
amino acid 220 in comparison to the human-adapted NS1 protein, which retained a 78 
typical NS1 length of 230 residues (5). A functional difference in the swine-origin 79 
NS1 was reported by Hale et al. (7) and confirmed by us (8) whereby the ability to 80 
bind to the human host cell factor CPSF 30 and limit host gene expression had been 81 
lost by the accumulation of at least 3 mutations in the C-terminal domain of the NS1 82 
gene. Thus the virus that crossed from pigs to humans and sparked the 2009 83 
pandemic was not optimized for human replication and transmission because its 84 
gene segments were swine-adapted. 85 
In the United Kingdom, there were two waves of A(H1N1)pdm09 activity during the 86 
2009-10 pandemic period: an initial out-of-season outbreak that started in April 2009 87 
and peaked in July 2009, followed by a second wave in the autumn and winter of 88 
2009-2010. In the first post-pandemic winter (2010-11), a third wave of 89 
A(H1N1)pdm09 activity was seen. This third wave was associated with an increase 90 
in infection and severity, and a shift in age demographics from children (0-15 years) 91 
and younger adults (16 to 44 years) to predominantly adults (9–12). Compared with 92 
the first two pandemic waves, the third wave was associated with more hospital 93 
admissions (8797 vs 7879  people), more people admitted to critical care (2200 vs 94 
1700  people) and a greater number of deaths (474 vs 361 people) in England (13). 95 
Although there had been evidence of sequence variation in viruses in the second 96 
pandemic wave in the UK and elsewhere (14, 15), surveillance and antigenicity 97 
studies had reported no change in the antigenicity of the surface glycoproteins 98 
haemagglutinin (HA) and neuraminidase (NA), so a vaccine update was not 99 
warranted (14). Moreover, any change in antigenicity is unlikely to explain the 100 
increased severity of third wave viruses in the unvaccinated or those who had not 101 
previously contracted the virus. Nonetheless, it is possible that other genetic 102 
changes distinct from those with an antigenic effect may have led to increased 103 
circulation of the virus or enhanced virulence that accounted for the apparent 104 
increased severity in the UK’s third wave.  Indeed, Dorigatti and Ferguson recently 105 
modelled the UK third wave and concluded that the observed increased numbers of 106 
cases were most likely accounted for by an increase in virus transmission with a 107 
commensurate increase in the numbers of severely ill. They suggested this could  be 108 
due to weather conditions that winter being particularly cold and dry and favouring 109 
virus transmission events, or to a change in the inherent transmissibility of the virus 110 
itself, or both (16). Here we report genetic variability across the three waves of 111 
influenza A(H1N1)pdm09 in the UK and identify non-synonymous variants that 112 
define the third wave viruses. We show that mutations in HA and NA, the PA 113 
component of the polymerase complex and the NS1 interferon antagonist protein 114 
enhanced the virus’ ability to replicate in human airway cells.  115 
  116 
Materials and methods 117 
Cells. Madin-Darby canine kidney (MDCK), Human embryonic kidney (293T), and 118 
Newborn pig tracheal (NPTr), cells were grown in Dulbecco’s Modified Eagle 119 
Medium (DMEM) supplemented with 10% Foetal calf serum (FCS). Mucil-Air™ 120 
cultures of human nasal epithelium (HAE) (Epithelix) were grown in Mucil-Air media. 121 
All cells were maintained at 37C in 5% CO2. 122 
Patient recruitment and sampling. MOSAIC recruited adult and paediatric patients 123 
admitted to hospital with suspected influenza virus infection in London and Liverpool 124 
between December 2009 and February 2011. Infection with seasonal influenza A 125 
H3N2, influenza B or A(H1N1)pdm09 viruses was confirmed locally by viral PCR 126 
according to regional protocols. Patients were approached for recruitment and initial 127 
(T1) sampling as soon as possible following admission to a MOSAIC-associated 128 
hospital. Nasopharyngeal aspirate and viral throat swab samples were obtained 129 
according to the study SOP. Patients with comorbidities were not excluded. Different 130 
severities of illness were included and severity was graded as follows: grade 1 = no 131 
respiratory compromise (oxygen saturation >93% on room air); grade 2 = respiratory 132 
compromise requiring non-invasive oxygen supplementation; grade 3 = respiratory 133 
compromise requiring invasive mechanical ventilation and oxygen supplementation. 134 
The MOSAIC study was approved by the NHS National Research Ethics Service, 135 
Outer West London REC (09/H0709/52, 09/MRE00/67). 136 
Viruses. Influenza viruses were isolated from clinical specimens by the Respiratory 137 
Virus Unit, Public Health England, Colindale, London. Briefly, clinical specimens 138 
including nasopharyngeal aspirate (NPA), viral throat swab in virus transport media 139 
(VTM), bronchial alveolar lavage (BAL) or endotracheal aspirate (ETA) were 140 
transported to PHE frozen on dry ice. For virus isolation 200µl clinical specimen was 141 
inoculated onto monolayers of Madin-Darby Canine Kidney (MDCK) cells or the 142 
SIAT-1 cell derivative in virus isolation tubes and allowed to adsorb for one hour 143 
(17)Cells were incubated in serum-free Earles MEM in the presence of 1.25 µg/ml 144 
TPCK-treated trypsin (Worthington) on a rolling drum at 33°C for a maximum of 145 
seven days with regular observation for viral cytopathic effect (CPE). Blind passage 146 
on fresh cells for a further 7 days was performed where necessary. Virus growth was 147 
determined by haemagglutination assay using turkey or guinea pig red blood cells. 148 
One further virus passage was made to generate a large stock of virus for 149 
distribution to the MOSAIC consortium. 150 
Plasmid based reverse genetics. The reverse genetics viruses were generated as 151 
previously described (8) from plasmids either synthesised (GeneArt) from 152 
A/England/195/2009 whole genome sequence and A/England/687/2010 segment 4 153 
sequence, or generated by site-directed mutagenesis (Stratagene Lightening 154 
mutagenesis kit) of A/England/195/2009 plasmid sequence with point mutations 155 
necessary to create A/England/687/2010 amino acid sequence. The plasmids were 156 
sequenced to confirm presence of required mutations and absence of unwanted 157 
variations. Primer sequences available upon request. Reverse genetics viruses were 158 
generated using the 12 plasmid system with either A/England/195/2009 or 159 
A/England/687/2010 polymerase I clones and helper polymerase of A/Victoria/3/75. 160 
Virus replication in cell lines and primary airway cultures. Confluent cell monolayers 161 
were infected with equal PFU of each virus at an MOI of 0.01 or 0.001 as specified in 162 
the main text. The cells were incubated in the inoculum for 1 hour then the inoculum 163 
was removed, cells washed with PBS and overlaid with DMEM supplemented with 164 
NEAA, Penicillin/Streptomycin and TPCK treated trypsin and incubated at 34C in 165 
5% CO2. Growth was assessed by well sampling at fixed timepoints and titrated on 166 
MDCK cells by plaque assay. For infection of Mucil-Air cultures™, the apical surface 167 
(air interface) was washed with serum free media prior to infection, then washed 168 
again after the inoculation. Viral titre was assessed by sampling from the apical  169 
surface by the addition of 200 μl of serum free media, incubation for 15 minutes and 170 
removal of the media. The basal layer was sampled for cytokine analysis, with an 171 
equal volume of Mucil-Air media replacing that removed. 172 
Virus competition assays. Mucil-Air™ cells were washed with serum free DMEM 173 
prior to inoculation with a 50:50 mix of two viruses at a total MOI of 0.001. The cells 174 
were incubated for one hour prior to removal of the inoculum and washing with SF 175 
media. The apical layer was sampled every 12 hours as above. Viral RNA was 176 
extracted from the supernatant with a Qiagen Qiamp vRNA kit and processed for 177 
Ilumina deep sequencing. Each assay was run in triplicate. 178 
Minigenome polymerase assays. The coding sequence for the PB1, PB2, PA, and 179 
NP proteins was amplified using KOD polymerase (Novagen) and primers containing 180 
restriction sites to allow incorporation into pCAGGs expression vectors. To introduce 181 
alternative amino acids into the coding sequence, site-directed mutagenesis was 182 
undertaken on the reverse genetic genomic plasmids. Primers are available on 183 
request. pCAGGs expression plasmids for PB1, PB2, PA and NP proteins were 184 
transfected onto a confluent layer of 293T cells using Lipofectamine 2000 and 185 
Optimem in the concentration ratio of 1:1:0.5:2 respectively, . Additionally a plasmid 186 
encoding a minigenome firefly luciferase reporter flanked by the promoter region of 187 
the influenza virus’ segment 8 and either a Renilla or β-galactosidase transfection 188 
control plasmid were co-transfected with the mini-genome complement. Cells were 189 
incubated with the transfection mix for 24 hrs at 34C at 5% CO2. Then supernatant 190 
was removed, the cells washed and 100 ul of passive lysis buffer added (Promega). 191 
The cells were freeze thawed and lysates analysed with the dual luciferase reporter 192 
system (Promega) on the FLUOstar OMEGA (BMG labtec). All assays were run in 193 
triplicate, with each assay being repeated a minimum of 3 times. 194 
Interferon reporter assays. A plasmid with the interferon β−promoter region upstream 195 
of a firefly luciferase reporter was transfected along with a β-galactosidase or Renilla 196 
control plasmid into 293T cells in suspension using Lipofectamine 2000 and 197 
Optimem. 293T cells were adhered to plates pre-treated with Poly-L-Lysine and 198 
incubated overnight. The cells were then infected with virus at an MOI of 3, 199 
incubated at 37C for one hour prior to inoculum removal, washing and overlaying 200 
with DMEM with 10% FCS. The cells were then harvested at set time points by the 201 
removal of media, washing with PBS and the addition of passive lysis buffer and 202 
passed through a freeze thaw cycle, prior to detection with the dual luciferase 203 
reporter system (Promega) on the FLUOstar OMEGA (BMG labtec). All assays were 204 
run in triplicate, with each assay being repeated a minimum of 3 times. 205 
Mouse experiments. All animal procedures and care conformed strictly to the United 206 
Kingdom Home Office Guidelines under the Animals (Scientific Procedures) Act 207 
1986 and the protocols were approved by the Home Office of Great Britain (License 208 
number: 70/6646). 209 
Fifteen weight matched female Balb/C mice anesthetized with isoflurane were 210 
inoculated with 7.5 x105 or 2x105 PFU of each influenza virus. Mice were weighed 211 
daily and any mice falling below a 30% weight loss threshold were sacrificed.  At day 212 
2 and day 4 post infection, 5 mice from each experimental group were sacrificed and 213 
the lungs harvested. Whole lungs were weighed and homogenised in the presence 214 
of 1 ML of PBS and split into aliquots. An aliquot of lung homogenate from each 215 
mouse was subjected to titration by plaque assay. Results are expressed in ML of 216 
the homogenate as whole mouse lungs were homogenised in a standardised volume 217 
of PBS.  218 
Interferon detection. Aliquots of mouse lung homogenate were tested for the 219 
presence of mouse interferon using the Verikine interferon α kit (R&D Systems) 220 
according to the manufacturer’s instructions and then measured on the FLUOstar 221 
OMEGA (BMG labtec). Each sample was run in duplicate. 222 
Phylogenetic analysis. Complete genomes of samples sequenced by the MOSAIC 223 
Consortium were aligned against all complete A/H1N1/09 genomes up to 2011 224 
present in NCBI’s Influenza Virus Resource database (18). To improve tree 225 
readability, this set of 2084 genomes was down-sampled using custom Python 226 
scripts, ensuring that the topology of the phylogenetic tree was maintained. 227 
Phylogenetic trees were inferred using a neighbour-joining clustering method with 228 
branch lengths and substitution parameters estimated using the Tamura-Nei model 229 
under the maximum composite likelihood method implemented in MEGA version 230 
6.06 (19). Tree robustness was evaluated by boostrapping with 1000 pseudo-231 
replicates. 232 
Statistical analysis. All statistical analysis was conducted using GraphPad Prism 233 
software®.  Virus replication, IP-10 and IFN cytokine production and the mucus 234 
inhibition assays were assessed by unpaired T-Tests compared to the A/195 first 235 
wave isolate. The interferon  and minigenome assays were assessed by repeated 236 
measures or ordinary one way anova with Tukey’s multiple comparison test as 237 
appropriate. 238 
  239 
Results 240 
The Mechanisms of Severe Acute Influenza Consortium (MOSAIC) study was 241 
formed to investigate why some individuals infected by the pandemic H1N1 influenza 242 
virus developed severe symptoms requiring hospitalisation whilst others developed a 243 
milder coryzal illness. MOSAIC recruited 85 patients admitted to hospital with 244 
influenza-like illness in the winter of 2009/10 and a further 172 in winter 2010/11. 245 
Nasopharyngeal aspirate (NPA) and viral throat swab specimens were collected 246 
from patients for attempted isolation of virus strains by culture in MDCK cells, 247 
assessment of viral titre by qRT-PCR and whole genome sequencing directly from 248 
the clinical sample. 249 
Evolution of influenza A(H1N1)pdm09viruses showed a distinct UK third wave 250 
lineage 251 
Clinical samples, either NPA or throat swabs that were positive for influenza   252 
A(H1N1)pdm09  RNA were prepared without virus isolation or passage and 253 
sequenced by either the Roche Genome Sequence FLX 454 or Illumina Genome 254 
Analyzer IIx platforms as previously described (20), and assembled into full genomes 255 
as described (21). Background whole-genome pandemic sequences were 256 
downloaded from NCBI’s Influenza Virus Resource database (18) and aligned 257 
against the UK first, second and third wave genomes. Phylogenetic analysis shows 258 
that viruses from the first two pandemic waves were closely related, consistent with 259 
the proposed persistence of the first wave lineages into wave two in the UK (20). 260 
However, viruses detected during the third wave (winter of 2010-2011) were 261 
genetically distinct, with the majority of genomes clustering in a separate 262 
monophyletic clade (Figure 1). Across the second and third waves in the UK, viruses 263 
from hospitalised patients were phylogenetically indistinguishable from community 264 
and non-hospitalised control patients and did not contain shared genome variants 265 
that could confer an enhanced pathogenicity (Figure 1).  We assessed amino acid 266 
changes fixed in the majority of viruses, identifying 21 common changes across all 267 
segments of which 12 were unique to third wave viruses (Table 1). These changes 268 
also accumulated in second and third wave virus isolates from other regions of the 269 
UK and from the rest of the world (Table 2), except for G189D in NS1. We also 270 
checked for nucleotide differences in segment 2 that would affect the translation of 271 
PB1-F2 and/or N40 open reading frames but found none. 272 
Clinical isolates from the first, second and third pandemic wave varied in their 273 
growth kinetics in primary human airway cultures. 274 
The lack of a common genetic difference between influenza viruses isolated from 275 
severe or mild influenza cases in each wave suggests that the observed increase in 276 
overall severity in the third wave may be related to a general property of wave three 277 
viruses, which should be reflected in virological differences between first, second 278 
and third wave viruses.   279 
To assess virus differences we isolated virus from clinical samples in SIAT-MDCK 280 
cells for a subset of viruses selected in accordance with their placements on the 281 
phylogenetic tree in figure 1. We infected MDCK cells or primary human airway 282 
epithelial (HAE) cultures or mice with 9 different clinical isolates from the second 283 
wave (3 viruses) and the third wave (6 viruses), and compared growth and outcome 284 
of infection with the first wave prototypic UK A(H1N1)pdm09 virus, 285 
A/England/195/2009. Clinical data from patients from whom these isolates were 286 
obtained are shown in Table 3.  We recorded the differences in viral RNA load in 287 
NPA at time of recruitment (T1 NPA titre), the severity score for the patient and the 288 
presence of patient co-morbidities. With the caveat that the delay between symptom 289 
onset and recruitment varied from patient to patient (day since symptom onset), we 290 
did not find any correlation between viral load and severity score for this subset of 291 
the MOSAIC cohort.  292 
In vitro, first, second, and third wave viruses used to infect MDCK cells did not show 293 
a consistent difference in replication pattern according to respective waves, although 294 
there was small variation between individual isolates (Figure 2A). In HAE cell 295 
cultures the pattern of virus replication was more diverse and correlated with 296 
respective waves. Although two viruses, one from the second (A/47) and one from 297 
the third wave (A/213), displayed similar growth kinetics to the prototypic A/195 virus, 298 
most second and third wave viruses displayed a growth advantage at 24 and 48 299 
hours post-infection in human airway cells. Using a different HAE culture code 300 
(primary cells obtained from a different donor), a representative third wave clinical 301 
isolate, A/687, displayed a consistent 2 log10 growth advantage at the 24 and 48 302 
hour time points, with a peak titre of 108 PFU/ml compared with 106 PFU/ml for the 303 
A/195 first wave virus at 48 hours post infection (p=0.02) before the virus titres 304 
became similar at 72 hours post infection (Figure 2c). Strikingly, in pig tracheal cell 305 
cultures (NPTr) the third wave virus A/687 was compromised in growth (Figure 2c). 306 
In other human lung cell lines such as Calu-3 the 1st wave virus also replicated more 307 
efficiently than the 3rd wave virus although the difference was not as pronounced as 308 
in the pig cell line.  This suggests that the adaptation in 3rd wave virus might be 309 
conferred by features only present in the well differentiated complex HAE cultures. 310 
Outcome of infection in the in vivo Balb/c mouse model did not correlate with 311 
patient severity or growth in human airway cultures. 312 
In order to assess the in vivo characteristics of this panel of clinical isolates we 313 
utilised a mouse model. Balb/c mice were infected intranasally with each of the panel 314 
of viruses. After a dose of 2 x 105 PFU, the A/195 first wave isolate caused >20 % 315 
weight loss by day 5 post infection (Figure 3a). Some of the second and third wave 316 
viruses inoculated at the same dose were less pathogenic in mice as ascertained by 317 
less weight loss, for example the A/687 third wave virus induced only 2% weight loss 318 
and no mortality (Figures 3b & c). Mouse mortality (due to humane cull through 319 
weight loss )was observed in all three of the sets of mice infected with the second 320 
wave viruses, but only in two sets (A/689 and A/672) of the third wave infected mice. 321 
Statistically, only the A/09 infected mice did not show a difference in weight loss to 322 
the A/195 infected mice, the A/47 and the A/689 mice groups displayed a statistical 323 
difference only on two and three days respectively.  The differences in weight loss 324 
and mortality in mice did not correlate with the severity scores assigned to the 325 
human patients infected with the same virus (Figure 3a, b & c and Table 3). 326 
Interestingly, the viral loads in the mouse lung at day 2 or 4 post infection did not 327 
show the same pattern as titres in HAE culture infections, with a trend towards lower 328 
virus lung titres at day 2 for the second and third wave viruses compared to A/195 329 
(Figure 3d). For example, the first wave A/195 virus replicated to high levels in mice, 330 
whereas the third wave A/687 virus replicated comparatively poorly, but in HAE cells 331 
the situation was reversed (figure 2c). However in some cases the reciprocal pattern 332 
between HAE replication and mouse pathogenicity was not maintained: A/672, which 333 
had similar growth in HAE as A/687, replicated to a higher titre, induced high weight 334 
loss of around 15 % and led to 20 % mouse mortality. There are only four coding 335 
genetic differences between these two third wave viruses: HA L176I; NS1 I123V, 336 
PB1 I12T and PB2 N556S.  337 
The most obvious trait that associated with virus wave was a clear association 338 
between the interferon (IFN) α level in the mouse lung and the wave of isolation for 339 
each virus; levels of IFN in lungs of mice infected with second wave viruses were 340 
lower than for A/195, and the lowest IFN levels were in third wave virus infected mice 341 
lungs (Figure 3e).  The lower IFN production as the waves progressed could reflect 342 
the virus adapting to better control the host immune system. The same patterns of 343 
weight loss, lung titres and lung interferon levels for each isolate were observed in a 344 
separate experiment where mice were infected with 7.5 x 105 PFU (data not shown). 345 
Virus with segment 8 of the third wave virus induced less type I interferon. 346 
The increased interferon in lungs of mice infected with first wave virus might be 347 
driven by higher viral loads. However viral loads in lung at day 2 were not always 348 
higher in mice infected by second wave than by third wave viruses, but IFN levels 349 
were higher (Figure 3d and e). We hypothesized that mutations in the virus between 350 
second and third wave may have enhanced the virus’ ability to control the innate 351 
immune response. NS1 protein encoded on RNA segment 8 is the major interferon 352 
antagonist of influenza A virus. Sequence analysis showed third wave viruses 353 
possessed a cluster of amino acid changes in the NS1 protein, in various 354 
combinations at positions E55Q, P114T, I123V,and G189D (Table 1). A third wave 355 
isolate A/687 possessed three of these changes within the effector domain of the 356 
NS1 protein; 114T, 123V and 189D. The G189D variation also changed the coding 357 
sequence of the NEP protein (V32I) because the NS1 and NEP open reading frames 358 
overlap at this region. Under the conditions used for these assays IFNβ was 359 
undetectable in apical washes or in basal medium from infected HAE cultures. 360 
Therefore we assessed the virus’ ability to counteract the production of an innate 361 
induced cytokine, IP-10. At 16 hours post infection with a high multiplicity of virus, 362 
significantly less IP-10 was secreted from HAE cells infected with the A/687 virus 363 
compared to the first wave virus A/195 (Figure 4a). Levels of two other cytokines, IL-364 
6 and IL-8 were also lower in basolateral media following infection of the HAE cells 365 
with 3rd wave virus (data not shown) but the difference did not reach significance. 366 
IFN was not detectable in samples collected form the HAE cells after infection with 367 
either virus. 368 
To further assess the role of the NS gene mutations in controlling the cytokine 369 
response, we generated recombinant viruses with the segment 8 RNAs exchanged. 370 
The A/195 reverse genetics (RG) system described previously was generated by 371 
synthesizing the cDNAs for this strain de novo (8, 22). The A/687 reverse genetics 372 
virus was created by site-directed mutagenesis of the A/195 plasmids wherever an 373 
amino acid change was present, for seven of the gene segments. The gene segment 374 
encoding the A/687 HA was synthesised de novo.  375 
293T cells transiently transfected with an IFNβ promoter luciferase reporter construct 376 
were infected with each of the 7:1 single gene reassortant viruses or with the 377 
isogenic A/195 or A/687 wild type reverse genetics (RG) viruses (Figure 4b) (23). 378 
The A/687 RG virus induced a significantly lower luciferase signal than A/195. The 379 
induction of the IFN β promoter was decreased relative to isogenic A/195 virus when 380 
the 687 NS gene was present, and significantly  increased for the A/687 virus with 381 
A/195 NS..  382 
Since there was also a difference in NEP coding between these two viruses we 383 
tested whether the NS1 itself had altered activity as an interferon antagonist when 384 
expressed exogenously. At 3 different doses of NS1 expression, the 3rd wave NS1 385 
protein was significantly better able to control the expression of luciferase driven by 386 
an interferon promoter in NDV infected cells (Figure 4c).   387 
The HA and NA genes of third wave viruses displayed different receptor 388 
binding preferences, enhanced infectivity in human mucus and conferred 389 
enhanced growth in HAE cell cultures over first wave viruses. 390 
Second and third wave UK viruses displayed wave-associated amino acid changes 391 
in the HA and NA protein (Table 1). A collection of eleven MOSAIC virus isolates 392 
representative of the three waves and including A/195 (first wave), A/06 (second 393 
wave), and A/675 and A/687 (third wave) from the panel of nine viruses studied 394 
above, were tested in a haemagglutination assay using erythrocytes from different 395 
species (guinea pig, turkey and chicken), which are known to differ in the specificity 396 
and density of sialic acids expressed on their cell surface (24). All viruses displayed 397 
comparable binding to guinea pig and turkey erythrocytes, but the second and third 398 
wave isolates displayed lower binding to chicken red blood cells relative to A/195 399 
(Figure 5a). The only exception was A/675, which has an M227I (230 in H3 400 
numbering) amino acid variation near the receptor-binding pocket and retained 401 
strong binding to chicken erythrocytes. HA assays performed with RG A/195 and 402 
A/687 viruses recapitulated the general pattern seen for the panel of isolates; the 403 
relative binding of the first wave virus for chicken erythrocytes was higher than for 404 
the third wave virus (Figure 5b).   405 
A/687 virus differs from A/195 by eight amino acids in the HA protein and four in the 406 
NA protein. To test if the changes in HA and NA alone were sufficient to confer the 407 
observed growth advantage in human airway cells (Figure 2b and c), we generated  408 
6:2 recombinant viruses with the A/687 HA and NA combined with A/195 internal 409 
proteins or  the A/687 internal genes with the HA and NA of A/195, and compared 410 
their replication with that of isogenic wild type RG A/195, or RG A/687. The virus with 411 
the A/687 internal genes coupled with 1st wave HA and NA replicated to a lower titre 412 
than whole A/687 virus, and conversely the virus with A195 internal genes and 3rd 413 
wave HA and NA replicated to higher titres than whole A/195 virus. However the 414 
differences in replication did not reach statistical significance (Figure 5c). This 415 
suggests that both internal and external genes contribute to the enhanced replication 416 
of 3rd wave virus in HAE cultures but neither genes sets are sufficient to reproduce 417 
the phenotype alone.  418 
To investigate a role for the third wave NA protein in enhanced replication in HAE 419 
cultures, we generated a 7:1 RG virus with 7 segments from the A/195 virus and 420 
RNA segment 6 which encodes the NA protein from A/687. This virus and the 421 
isogenic A/195 virus were then incubated in the presence of human respiratory 422 
mucus for 60 minutes prior to infection onto MDCK cells. The number of plaque-423 
forming foci were counted and the percentage reduction in infectivity was calculated 424 
(25). The virus carrying the third wave NA gene segment displayed an increased 425 
ability (p=0.044) to overcome inhibition of infectivity by human mucus, which is an 426 
important factor in the ability of virus to infect and spread in the human airway 427 
(Figure 5d).  428 
The mutation in PA, N321K of third wave viruses conferred enhanced 429 
replication in a minireplicon assay and in viral competition assays. 430 
Mutations in other genes of the second and third wave viruses may have also 431 
contributed to human adaptation and enhanced replication in HAE. In the 432 
polymerase proteins and nucleoprotein of the A/687 virus there were seven amino 433 
acid changes from A/195 polymerase genes, three of which were unique to the 434 
majority of the third wave viruses in the UK. These three changes are at PB2 435 
V344M, I354L and PA N321K (Table 1).  436 
In order to assess whether these amino acid changes altered the activity of the viral 437 
polymerase, we created two sets of expression plasmids that allowed reconstitution 438 
of polymerase components from either A/195 or from A/687 virus. For the A/195 439 
constellation we used a PA plasmid with the glycine 3 mutated to aspartic acid, since 440 
this difference was atypical amongst first wave viruses (17). Each viral polymerase 441 
was reconstituted in a minireplicon reporter assay in 293T cells as previously 442 
described (26). The third wave A/687 polymerase and nucleoprotein complex 443 
consistently directed higher amplification and expression of the luciferase signal from 444 
the minireplicon in human cells than the A/195 polymerase constellation (p=<0.001) 445 
(Figure 6a).  446 
In order to discern if this enhancement of polymerase activity was a result of amino 447 
acid changes in a single protein, the minireplicon assays were carried out with single 448 
protein exchanges. A dramatic 10-fold decrease in signal was observed when the 449 
A/195 PA protein was paired with the A/687 PB1, PB2 and NP proteins. The 450 
reciprocal exchange saw the converse result, although the increase in polymerase 451 
activity when A/687 PA was introduced into the A/195 polymerase constellation was 452 
not statistically significant (Figure 6a).  453 
To assess whether the PA N321K mutation led to an enhancement of replication in 454 
the context of whole virus, we generated a 7:1 (PA) RG virus in which every genomic 455 
segment except for the A/687 PA segment that was derived from A/195. Replication 456 
competition experiments starting with a 50:50 mix in triplicate HAE cultures were 457 
analysed by deep-sequencing using Illumina sequencing technology, and showed 458 
the virus with the PA 321K from the third wave genotype rapidly dominated the viral 459 
RNA population in all 3 biological replicates, (p=0.0078, <0.0001 and <0.0001 at 48, 460 
72 and 96 hours respectively when assessed as a percentage of total reads in the 461 
unpaired T test), illustrating a growth advantage in human cells conferred by this 462 
amino acid change (Figure 6b).  463 
  464 
Discussion 465 
In the UK there was a reported increase in severity of the pandemic H1N1 virus as 466 
the waves of influenza infection progressed from its emergence in spring 2009 until 467 
end of winter 2011(10, 12). It has been suggested that this can be attributed to a 468 
shift in the behaviour of the infected population due to a change in public health 469 
responses (10, 13). However this explanation does not exclude host adaptations in 470 
the influenza virus itself that might also have contributed to the change in severity 471 
associated with A(H1N1)pdm09 infection. If the virus was responsible, there may 472 
have been a specific virulence factor that appeared in many or all of the hospitalised 473 
cases, however we find no evidence for this here. We can discern from whole-474 
genome sequence data provided by FLUWatch, FF100, PHE, RCGP and the 475 
isolates derived from the hospitalised MOSAIC patients over three waves of infection 476 
in the UK, that the viruses derived from hospitalised patients did not vary genetically 477 
from those found within the community, consistent with Galliano et al. for the second 478 
wave (27). 479 
Alternatively, a constellation of adaptive changes that accumulated in the virus as it 480 
circulated in the community could make it more likely that a higher proportion of 481 
individuals would become infected, with possibly more efficient early virus 482 
replication, leading to more severe infection in some people.  483 
A great deal of effort worldwide has been put into tracing amino acid changes in the 484 
pandemic H1 HA, and to a lesser degree the NA (28–37). This emphasis on the 485 
glycoproteins is understandable due to their antigenic properties and importance in 486 
determining antiviral susceptibility. Indeed, various functional consequences of 487 
naturally occurring amino acid changes in the NA and HA proteins have already 488 
been demonstrated using animal models (38–43). In our MOSAIC hospitalized 489 
cohort we did not detect specific HA mutations described by others to affect 490 
A(H1N1)pdm09 virulence, for example HA D222G, which purportedly facilitates 491 
better binding to α2,3 linked sialic acid-linked receptors in the lower respiratory tract 492 
(44–47), changes in glycosylation (48) or antigenicity (49) were not present. Other 493 
groups have suggested that HA D222G is relatively common is severe cases (44–494 
47).The D222G mutation has been suggested to sometimes arise during virus 495 
culture as an artefact, and may also only be present as a minority variant in samples 496 
taken at  certain times during the infection.  We do not know why it was not detected 497 
in our MOSAIC cohort. 498 
We detected a different type of phenotypic change associated with the HA protein of 499 
the third wave viruses compared to the first wave isolate. A comparison of the 500 
viruses’ relative ability to haemagglutinate chicken, turkey, or guinea pig red blood 501 
cells indicated a relative increase in affinity to α-2-6 linked sialic acids and a 502 
concomitant decrease in the ability to bind to α-2-3 linked sialic acids for the majority 503 
of the third wave isolates. This alone may have increased the ability of the virus to 504 
infect the human upper respiratory tract, accounting for the greater replication of 505 
A/687 in HAE cells. That the lost affinity for the α2-3 sialic acids is observed in both 506 
second and third wave isolates would implicate one or more of the previously 507 
reported variations in the HA I32L, D97N, S185T, E374K and S451N (27). A recent 508 
publication by de Vries et al. (50) indicated a change in receptor binding caused by 509 
an S185T mutation. We also note the recent publication from Cotter et al. (51) 510 
showing that later isolates of A(H1N1)pdm09 virus contained pH-stabilising 511 
mutations in HA, which enhanced their replication in the ferret upper respiratory tract. 512 
This mutation at HA residue E374K (H1 numbering), is present in 5 of 6 third wave 513 
viruses in our subset (Table 1) and may also have contributed to the increased 514 
replication in HAE cultures we observed (Figure 2b).  515 
There may also be a contribution of NA to the increased propagation of third wave 516 
virus in HAE (Figure 5c). All of the second and third wave viruses in our cohort had 517 
NA mutations V106I and N248D compared to first wave A/195. These are proposed 518 
to enhance viral stability though modifications in pH tolerance in acidic conditions, 519 
although we did not assess this phenotype (52). However, we did observe an 520 
increase in the ability of virus with third wave NA to retain its infectivity in human 521 
mucus, a property linked with efficient replication in HAE and transmission in ferrets 522 
(23). Several other research groups have already investigated variation between 523 
individual isolates of the A(H1N1)pdm09 lineage. These publications describe a few 524 
selected isolates without considering their phylogenetic relationships, from mild, 525 
severe or fatal cases, and characterize their sequences and phenotypes in various 526 
animal models (41, 53–55). A correlation has sometimes been observed between 527 
the outcome of infection in animal models and the severity of the human case from 528 
which the isolate had been obtained; this was not the case in our study. Rather, we 529 
find increased replication in primary human cells is often accompanied by decreased 530 
virulence in the murine model.  It is well recognized that the mouse is not a good 531 
model host for human-adapted influenza viruses. 532 
Our work suggests that changes to internal viral proteins, including NS1 and PA, 533 
occurred during evolution of the third wave viruses and adapted them for increased 534 
replication in human cells. Others have also recently suggested that mutations have 535 
occurred in the virus polymerase since its transfer to humans that may enhance 536 
replication or transmission (56, 57). These previously described mutations may 537 
contribute to some of the enhanced polymerase activity we measured for the A/687 538 
third wave virus polymerase, but our in vitro polymerase reporter system also 539 
indicated that the N321K amino acid change in the PA protein, not previously 540 
reported, drove enhancement of viral polymerase activity. How it may achieve this is 541 
unclear. PA is known to interact with host factors such as transcriptional modulator of 542 
RNA polymerase II (RNAPII) hCLE (58, 59) and the minichromosome maintenance 543 
complex (60). The PA gene segment of A(H1N1)pdm09 virus was originally derived 544 
from an avian source during the formation of the TRIG internal gene cassette. 545 
Bussey et al. have already described three amino acids (85I, 186S and 336M) 546 
present in the A(H1N1)pdm09 PA that are not usually present in PA of avian viruses. 547 
They concluded that these three mutations together may have contributed to the 548 
ability of this polymerase complex to function better in mammalian cells. The 549 
mutation at residue 336 is situated close to amino acid 321 on the crystal structure 550 
(61).  551 
PA 321K was, until now, rare in swine adapted influenza viruses, occurring in only 552 
1.85% of sequences of all influenza A subtypes, and 3% of swine H1N1 viruses 553 
before the emergence of A(H1N1)pdm09 in 2009. It will be interesting to see if there 554 
is an increase in the occurrence of a lysine at this position in swine as the 555 
A(H1N1)pdm09 virus circulates in pigs or is reintroduced to this host through contact 556 
with humans after the third wave. Only 2.06% avian isolates have PA 321K.  This 557 
amino acid does not occur in the PA segment of seasonal human influenza viruses 558 
but the prevalence of the lysine variation in human isolates of pandemic H1N1 559 
increased sharply as sequences from later in the pandemic were submitted to NCBI, 560 
supporting its prevalence during and after the third wave. We expected the 561 
advantage conferred by this single PA mutation engineered alone to be subtle and 562 
therefore analysed the effect using a competition assay rather than by direct 563 
comparison of growth curves. Previously we have shown that the NA mutation 564 
H275Y in 1st wave virus conferred a replicative cost that was not detected by growth 565 
curve analysis but only by competition assay (62)). Indeed we found that virus with 566 
the single PA change 321K outgrew  321N virus in 3 biological replicates of HAE 567 
cultures.  This type of fitness assay could be useful in predicting the selection of 568 
mutations that confer subtle advantage.   569 
The other gene segment we investigated in detail here was that which encodes the 570 
NS1 protein. Interestingly, we found a cluster of mutations in NS1 that slightly 571 
enhanced its ability to control the innate immune response, including IFN and other 572 
cytokines. In the murine model decreased virus titre in the lungs early in infection 573 
with third wave viruses may also have contributed in part to a decreased IFN 574 
production. However in human airway cultures where third wave virus replicated 575 
robustly, we observed decreased IP-10 production in comparison with A/195. We 576 
attribute this to changes in NS1 because other known antagonists of the interferon 577 
response such as PB1-F2 were not different between these two viruses. Moreover, a 578 
6:2 recombinant virus with HA and NA from 3rd wave on 1st wave internal gene 579 
constellation induced higher IP-10 and other cytokine responses in HAE cells than 580 
whole 1st wave virus (data not shown). This suggests that the differences in cytokine 581 
response were not accounted for in this case by changes in receptor binding 582 
specificity that affected ciliated vs nonciliated cell  tropism in the HAE cultures as 583 
suggested by Ramos et al. 2011(63)). One explanation for our findings is that the 584 
NS1 protein had acquired some ability to bind to host cell factor CPSF30 and inhibit 585 
host mRNA processing, a mechanism by which other human-adapted influenza 586 
viruses have enhanced their control of the human innate immune response (64, 65).  587 
Indeed, exogenous expression of the A/687 NS1 gene inhibited the expression of a 588 
reporter gene from a polymerase II promoter significantly more efficiently than the 589 
NS1 gene from A/195 did (data not shown). This property is associated with an 590 
ability to bind and inhibit CPSF30 and may account for the difference we observed in 591 
heterologous control of induced interferon (Figure 4c). Hale et al. had already 592 
predicted some mutations in A/California/04/2009 virus by which this could be 593 
achieved, one of which is common to  the A/687 NS1, G189D (7).  That study also 594 
reported rather subtle effects on virus replication for viruses that were engineered to 595 
have CPSF30 binding. Notably one virus isolated in the third wave, A/689, which 596 
phylogentically lies closer to second wave viruses, was associated with higher 597 
cytokine levels than other third wave viruses in mouse lungs.  598 
In conclusion, using a collection of A(H1N1)pdm09 viruses chosen based on 599 
phylogenetic divergence we have shown amino acid changes in HA, NA, NS1 and 600 
PA in later waves led to functional changes in individual viral genes that conferred 601 
increased replication in primary human airway cells, suggestive of human 602 
adaptation. The increase in viral fitness overall may facilitate increased transmission 603 
as suggested by Doriggati and Ferguson (2013) but the lack of virus genetic 604 
differences between severe and community influenza cases suggests these changes 605 
are not on their own sufficient to confer severe disease (16), especially as there is 606 
evidence of high levels of asymptomatic or unreported illness during the first three 607 
waves of A(H1N1)pdm09 virus activity in the UK (12).  Infection of those predisposed 608 
to more severe disease may have been more likely in the third wave because of the 609 
differences in viral replication, host immune modulation and viral persistence in the 610 
host and the external environment (66–68).  611 
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  934 
Figure Legends 935 
Figure 1. Phylogenetic relationship of complete influenza A(H1N1)pdm09 genomes.  936 
The tree is rooted on A/California/04/2009, shown as a blue-filled circle. UK first-937 
wave isolates are highlighted as blue circles, while isolates sequenced by the 938 
MOSAIC consortium are shown as red circles for second wave community and 939 
hospitalised patients respectively, and green circles for third wave community and 940 
hospitalised patients respectively. Isolates characterised in this study are indicated 941 
with coloured arrows, while the inferred ancestral location of the asparagine-lysine 942 
mutation in PA is indicated with a black arrow. Nodes with bootstrap support >75% 943 
are highlighted with asterisks. The scale bar represents 0.002 substitutions/site. 944 
Figure 2. Replication of A(H1N1)pdm09 viruses in cell culture. 945 
  946 
Viral growth of 10 clinical isolates from first wave (blue), second wave (red), or third 947 
wave (green) in a) MDCK cells and b) human nasal Mucilair™ cell cultures (HAE) 948 
(Epithelix). Cells were infected at an MOI of 0.001 (MDCK cells) 0.01 (Mucilair™) 949 
and incubated at 34oC, the dashed line represents the mean of A/195.Statistics in 950 
the tables adjoining the chart keys were calculated using unpaired t-tests with Holm-951 
Sidak corrections.  952 
c) Replication of a representative first wave (A/195, blue circles) and  third wave 953 
(A/687, green squares) virus pair were assessed in HAE cells, (left panel) MDCK 954 
cells (left middle panel), CALU3 cells (right middlepanel) and  pig tracheal cells 955 
(NPTr) (right panel). Cells were infected at MOI of 0.001. Statistics were calculated 956 
using unpaired t-tests. 957 
Figure 3. Infection of mice with A(H1N1)pdm09 viruses  958 
Weight loss following infection of fifteen Balb/C mice inoculated intranasally with 2 959 
x105 PFU of virus isolates , a) one A/195 first wave isolate (blue), b) three 2nd wave 960 
isolates (red) and c) six 3rd wave isolates (green). Weight in mice inoculated with 961 
PBS is shown in black. Virus titre (d) and interferon levels (e) in lung homogenate at 962 
day 2. (f) Mouse mortality data for virus infections where weight loss necessitated 963 
cull. 964 
Figure 4. Cytokine induction by first and third wave virus and the role of NS gene 965 
segment in virus replication in HAE. 966 
a) Human nasal Mucilair™ cell cultures (HAE) (Epithelix) were infected in triplicate 967 
with RG A/195 and A/687 virus at MOI of 1 for 16 hours. The basal media was 968 
harvested and levels of the cytokine IP-10 measured using mesoscale discovery 969 
(MSD) plates. Stats: Unpaired t-test. 970 
b) 293T cells transiently transfected with an interferon b promoter luciferase reporter 971 
plasmid were infected with RG viruses A/195 (dark blue), A/195 with A/687 segment 972 
8 (light green), A/687 (dark green) and A/687 with the A/195 segment 8 (light blue) at 973 
an MOI of 3. Infection with Newcastle Disease Virus NDV was used as positive 974 
control. Stats: one way anova, with Turkey’s multiple comparison test (and 975 
associated adjusted p values). 976 
c) 293T cells transiently transfected with an interferon b promoter luciferase reporter 977 
and pCAGGs NS1 plasmids A/195 (blue), A/687 (green) and H3N2 (purple). 978 
Stimulated with NDV. Stats: one way anova with Turkey’s multiple comparison test. 979 
Figure 5. Variation in surface genes HA and NA in third wave virus leads to altered 980 
receptor binding, enhanced replication in HAE cells and enhanced infectivity in 981 
mucus.  982 
a) Haemagglutination assay with 11 clinical isolates from first wave (blue), second 983 
wave (red) and third wave (green) assessed for binding to 0.5% chicken, turkey or 984 
guinea pig red blood cells, the dashed line represents the A195 HA score. . b) 985 
Haemagglutination assay with equal PFU of A/195 first wave (blue) and A/687 third 986 
wave (green) RG viruses with 0.5% chicken or turkey red blood cells. c) Viral 987 
replication in human nasal Mucilair™ cell cultures (HAE) (Epithelix) of RG viruses 988 
based on  A/195 with HA and NA from A/195 first wave (blue)  or HA and NA of 989 
A/687 third wave (green triangle) d) A/687 (green square) or A/687 with  A/687 with 990 
HA and NA from A/195 (blue triangle)-. Cells were infected at an MOI of 0.01.* p < 991 
0.05 by unpaired t test. 992 
e) Mucus inhibition assay. An equal PFU of A/195 (blue) or A/195 with A/687 third 993 
wave NA (green) RG virus was incubated with diluted human mucus for one hour 994 
prior to infection on MDCK cells. Infectivity remaining was plotted as a percentage of 995 
titre in absence of mucus. * p,0.044 by unpaired t test. 996 
 Figure 6. PA of third wave virus confers enhanced polymerase activity and a fitness 997 
advantage in HAE cells. 998 
 a) Activity of polymerase reconstituted from plasmids expressing polymerase 999 
components of A/195 first wave (dark blue) and A/687 third wave (dark green) virus. 1000 
293T cells were transiently transfected with a plasmid that directs in situ synthesis of 1001 
a minigenome in which a luciferase reporter gene is flanked by the influenza A 1002 
promoter. Co-transfection of a Renilla expression plasmid was used to normalize for 1003 
transfection efficiency. Combinations of the PB1, PB2, PA and NP expression 1004 
plasmids of A/195 (blue) or A/687 (green) or lacking the PB2 polymerase (white) 1005 
were transfected. 24 hours post transfection cells were harvested. The results were 1006 
normalised to Renilla (transfection control) and are from three separate set of 1007 
experiments each with triplicate wells (n=9). Differences were analysed using one-1008 
way Anova test with Tukey’s multiple comparison test. 1009 
b) Human nasal Mucilair™ cell cultures (HAE) (Epithelix) were infected in triplicate 1010 
with RG viruses based on A/195 that differed only in PA at N321K. Virus released 1011 
was harvested at 24, 48, 72 & 96 hours and Illumina sequenced. The percentage of 1012 
N allele (first wave) is represented in blue and K (third wave) in green. 1013 
  1014 
Table 1) Amino acid changes observed in 10 A/H1N1 pdm(2009) viruses isolated in 1015 
the UK compared to prototypic virus A/England/195/2009. The three isolates from 1016 
the 2009-2010 season are above the line and the 6 isolates from 2010-2011 are 1017 
below.  1018 
Table 2) Prevalence ratios of amino acid changes in the UK and the rest of the 1019 
World (RoW) during the 1st, 2nd and 3rd waves of virus infection. Incomplete ratios are 1020 
due to unknown or multiple minor populations. HA numbering is H1.  1021 
 1022 
Table 3) Patient information for the MOSAIC viral isolates.  1023 
Severity score was assigned according to severity of respiratory impairment: grade 1 1024 
= no respiratory compromise (oxygen saturation >93% on room air); grade 2 = 1025 
respiratory compromise requiring non-invasive oxygen supplementation; grade 3 = 1026 
respiratory compromise requiring invasive mechanical ventilation and oxygen 1027 
supplementation. Predisposing (co-morbid) conditions included asthma, 1028 
immunosuppression etc. Collection month of sample the virus was isolated from and 1029 
sample types in which virus was detected (NPA – nasopharyngeal aspirate; nk: not 1030 
known). The time lag between onset of symptom and the viral sample is noted. Viral 1031 
titre was assessed by qPCR of the H1N1 NA gene and run against a standard curve 1032 










K R L I D N S T T S E K S N
UK 1st 82 17 UK 1st 87 13 98 98 62 38 99 1 100
RoW 1st 89 10 RoW 1st 94 6 99 1 99 63 37 97 2 99 1
UK 2nd 100 UK 2nd 94 6 95 2 100 98 2 68 31 97 3
RoW 2nd 98 2 RoW 2nd 96 4 94 6 99 94 5 68 30 99 1
UK 3rd 98 1 UK 3rd 100 27 73 16 82 99 1 11 86 15 84
RoW 3rd 97 1 RoW 3rd 100 44 56 16 83 100 6 94 16 84
PB2 NA
V M I L E G I V V I D N N K
UK 1st 100 100 97 3 UK 1st 58 42 99 1 57 42 100
RoW 1st 99 1 100 99 1 RoW 1st 77 23 98 77 23 100
UK 2nd 100 100 100 UK 2nd 99 1 99 1 99 100
RoW 2nd 97 2 99 99 1 RoW 2nd 97 3 99 98 2 98 1
UK 3rd 12 87 12 86 99 UK 3rd 98 1 12 87 99 1 13 85
RoW 3rd 18 81 19 81 100 RoW 3rd 76 24 14 85 99 1 15 85
PA M1
D G N K V I
UK 1st 88 12 100 UK 1st 100
RoW 1st 98 2 99 RoW 1st 100
UK 2nd 99 99 UK 2nd 100
RoW 2nd 99 99 RoW 2nd 100
UK 3rd 99 15 84 UK 3rd 17 82
RoW 3rd 100 21 78 RoW 3rd 20 80
NP NS1 NEP
I V P T I V A G D V I
UK 1st 55 45 UK 1st 100 54 46 100 100
RoW 1st 78 22 RoW 1st 100 42 58 100 100
UK 2nd 96 4 UK 2nd 100 4 95 2 100 100
RoW 2nd 97 3 RoW 2nd 99 6 94 99 1 99 1
UK 3rd 99 1 UK 3rd 61 39 2 96 2 85 15 85 15










Table 2) Prevalence ratios of amino acid changes in the UK and the rest of the World 
(RoW) during the 1st, 2nd and 3rd waves of virus infection. Incomplete ratios are due 


















mild' nk Apr-09 Nk nk Nk
A/England/06/2010
1 Yes Jan-10 20 NPA 5802
A/England/09/2010
1 Yes Dec-09 2 NPA 7035
A/England/47/2010





2 Yes Jan-11 1 NPA 47
A/England/672/2010
2 Yes Dec-10 4 NPA 0.2
A/England/675/2010
1 No Dec-10 2 NPA 2
A/England/687/2010
2 Yes Dec-10 2 NPA 8
A/England/689/2010
1 Yes Dec-10 2 NPA 1251
A/England/699/2010
3 Yes Dec-10 4 NPA 23
Table 3) Patient information for the MOSAIC viral isolates.
Severity score was assigned according to severity of respiratory
impairment: grade 1 = no respiratory compromise (oxygen
saturation >93% on room air); grade 2 = respiratory compromise
requiring non-invasive oxygen supplementation; grade 3 =
respiratory compromise requiring invasive mechanical ventilation
and oxygen supplementation.. Predisposing (co-morbid)
conditions included asthma, immunosuppression etc. Collection
month of sample the virus was isolated from and sample types in
which virus was detected (NPA - nasopharyngeal aspirate; nk:
not known). The time lag between onset of symptom and the viral
sample is noted. Viral titre was assessed by qPCR of the H1N1
NA gene and run against a standard curve of viral RNA of know
PFU/ML.
